Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05753150
Other study ID # MMV_TQ_18_01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 23, 2022
Est. completion date October 1, 2023

Study information

Verified date October 2023
Source Ministry of Health, Thailand
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this prospective, observational study is to assess the operational feasibility of appropriate radical cure treatment for P. vivax malaria with tafenoquine or primaquine, in patients 16 year and older, after G6PD testing in Thailand. The study will be implemented in a phased manner, in the provinces of Yala and Mae Hong Son. The first phase will be at higher level health facilities (hospitals). An interim analysis will be conducted after 40 patients are enrolled in the study in order to decide whether the study could be extended to lower level HFs. If approved by the Independent Study Oversight Committee, the study will be implemented in lower level HFs (malaria clinics).Higher level HFs will continue to include patients in the study during this 2nd phase.Written informed consent / assent is required from all patients /guardians in the case of minors.


Description:

This is a prospective, observational, multi-center, longitudinal study to be conducted in Yala province and Mae Hong Son province in patients with P. vivax malaria. Since 2020, quantitative G6PD testing has been available for routine use prior to providing PQ radical therapy at district hospitals and malaria clinics in the study provinces, in line with the national guidelines. Before study start, the relevant staff at all participating sites will be re-trained on the quantitative G6PD test procedure and the radical cure treatment algorithm by the Division of Vector Borne Diseases (DVBD). Standard operating procedures (SOP) for identification of patients with suspected AHA and guidance for initial management and transfer to a referral hospital will be provided. G6PD tests and TQ will be supplied to Health Facilities (HFs) by the DVBD using the usual supply route for drugs and diagnostics. PQ and other anti-malarial drugs are already available in Thailand. Within the study period, investigators will prospectively enroll all patients meeting the selection criteria. Each patient will have to sign an Informed Consent Form (ICF) indicating their consent for participation in the study by being considered for treatment with TQ provided that they have the appropriate G6PD enzyme activity (or treated with PQ, according to the current practice, otherwise) and permitting investigators to use their unidentified data for analysis purposes. Assent from patients <18 years of age, and the parent's or legal guardian's written informed consent must be obtained. This study will not change the patient/physician relationship, nor influence the investigator's drug prescription or therapeutic management of the patient other than what is specified regarding the algorithm for radical cure treatment of P. vivax malaria with TQ and PQ. As part of local practice in Yala province and Mae Hong Son province, patients treated for P. vivax infection are asked to return for a follow-up visit on Day 5 (+/- 1 day). This is in addition to the national policy of the first scheduled follow-up visit on Day 14 (+2/- 1 day) for vivax malaria patients. Patient data will be collected by the investigators on each patient visit. Any suspected case of AHA will be transferred to Yala Referral Hospital, the regional hospital with one board-certified haematologist or to the Mae Hong Son Provincial Hospital. Both hospitals have full services of blood transfusion, renal dialysis, and other life-saving procedures, for further investigation and treatment. As some patients may not return for the follow-up visits and might develop drug-induced AHA, the study staff at the referral hospitals will regularly screen hospital admission records for malaria patients participating in the study presenting signs of AHA, diagnosed with renal failure, and/or receiving blood transfusion. The study will be conducted in 2 phases: - 1st phase (for about 3 months): the study will be implemented in higher level HFs (hospitals). An interim analysis will be conducted after 40 patients (≥16 years old) with P. vivax are enrolled in the study in order to decide whether the study could be extended to lower level HFs. The decision will be made by an Independent Study Oversight Committee (ISOC). - 2nd phase (approximately 2 months): if approved by the ISOC, the study will be implemented in lower level HFs (malaria clinics). Higher level HFs will continue to include patients in the study during this 2nd phase. Final results will be reviewed by the ISOC. It is anticipated that it will take a total of about 11-12 months to complete data collection at the target hospitals and malaria clinics.


Recruitment information / eligibility

Status Completed
Enrollment 187
Est. completion date October 1, 2023
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Thai patient aged =16 years at enrolment - Diagnosed with a mono-species, uncomplicated P. vivax malaria that is parasitologically confirmed through standardized Giemsa microscopy. - Weighs >35 kg - Haemoglobin level must be >7gm% - Less than 24h away from emergency care Exclusion Criteria: - Participating in a clinical trial - Diabetic patients who are (1) being treated with metformin (because of possible increase in the risk of lactic acidosis due to metformin when administered in combination with tafenoquine) (2) G6PD-deficient and being treated with sulfonylureas e.g. Glucotrol, Glynase, Metaglip and Micronase (because of the increased risk of haemolysis in this population). - Pregnant/lactating women, women with suspected pregnancy.1 - Cases of severe/ complicated malaria

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tafenoquine
Tafenoquine 300 mg (2x150 mg tablets)
Primaquine
Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
Primaquine
Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)

Locations

Country Name City State
Thailand District Hospital Bannang Sata Yala
Thailand Malaria Clinic Bannang Sata Yala
Thailand District Hospital Kabang Yala
Thailand District Hospital Mae Sariang Mae Hong Son
Thailand Malaria Clinic Mae Sariang Mae Hong Son
Thailand Malaria Clinic Mueang Yala
Thailand District Hospital Sop Moei Mae Hong Son
Thailand District Hospital Than To Yala
Thailand Malaria Clinic Than To Yala

Sponsors (2)

Lead Sponsor Collaborator
Dr. Prayuth Sudathip Medicines for Malaria Venture

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Appropriate use of TQ based on G6PD activity Percentage of P. vivax patients aged =16 years treated or not with TQ in accordance with the appropriate level of G6PD enzyme activity 8 months
Secondary Appropriate use of PQ based on G6PD activity Percentage of P. vivax patients aged =16 years treated or not with daily PQ in accordance with the appropriate level of G6PD enzyme activity 8 months
Secondary Appropriate application of treatment algorithm Percentage of P. vivax patients who receive TQ or PQ based on the correct application of the treatment algorithm 8 months
Secondary Reported drug-induced AHA. Frequency of reported drug-induced AHA. 8 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05096702 - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting NCT05540470 - Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield N/A
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT03307369 - A Retrospective Study of Severe Plasmodium Vivax
Completed NCT01213966 - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Phase 2
Completed NCT00811096 - Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Phase 2
Terminated NCT03337152 - Assessing a Risk Model for G6PD Deficiency Phase 4
Completed NCT02751294 - A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT03377296 - Study of Controlled Human Plasmodium Vivax Infection N/A
Completed NCT00486694 - Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria Phase 2
Recruiting NCT05788094 - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Phase 4
Terminated NCT02110784 - Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Phase 2
Not yet recruiting NCT05690841 - FocaL Mass Drug Administration for Vivax Malaria Elimination Phase 3
Not yet recruiting NCT04739917 - Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers Phase 2
Completed NCT03208907 - DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil Phase 3
Completed NCT02184637 - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate Phase 1
Completed NCT01928914 - Tafenoquine Thorough QTc Study in Healthy Subjects Phase 1
Completed NCT00157885 - A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia. N/A
Completed NCT01081847 - Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants Phase 1